News CorMedix Inc.

Equities

CRMD

US21900C3088

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
5.19 ^USD	-2.63%		-4.24%	+38.03%

Apr. 15	CorMedix's DefenCath Now Commercially Available For US Inpatient Use	MT
Apr. 15	CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CORMEDIX INC. ANNOUNCES CMS GRANTS TDAPA TO DEFENCATH	Apr. 22	AQ
CorMedix Inc. Announces CMS Grants TDAPA to DefenCath	Apr. 19	AQ
CORMEDIX INC. ANNOUNCES U.S. INPATIENT COMMERCIAL AVAILABILITY OF DEFENCATH	Apr. 16	AQ
CorMedix's DefenCath Now Commercially Available For US Inpatient Use	Apr. 15	MT
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath® (Taurolidine and Heparin)	Apr. 15	AQ
CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	Apr. 15	CI
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference	Apr. 11	AQ
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 08	MT
CorMedix to Supply to DefenCath to Florida-based Dialysis Organization	Apr. 08	MT
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC	Apr. 08	AQ
CorMedix Inc. Announces Commercial Agreement with ARC Dialysis, LLC	Apr. 08	CI
CorMedix Inc. to Present at the Needham Annual Healthcare Conference	Mar. 27	AQ
Sector Update: Health Care Stocks Ease Wednesday Afternoon	Mar. 13	MT
CorMedix Remains Encouraged on DefenCath Opportunity, RBC Says	Mar. 13	MT
RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	Mar. 13	MT
Transcript : CorMedix Inc., Q4 2023 Earnings Call, Mar 12, 2024	Mar. 12
CorMedix: Q4 Earnings Snapshot	Mar. 12	AQ
CorMedix Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 12	CI
CorMedix Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	Mar. 12	AQ
CorMedix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News CorMedix Inc.

Equities

CRMD

US21900C3088

Summary

Filters